From preclinical to clinical
A leading explorer of drug-target interaction
« Exploring a therapeutic target under its physiological conditions yields crucial information for developing highly effective molecules, while at the same time significantly reducing their side effects. Our proprietary technologies enable us to achieve this feat. »
Dr Pierre Eftekhari, President